In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Catabasis, Sarepta ally in combo therapy for DMD

Executive Summary

Catabasis Pharmaceuticals Inc. and Sarepta Therapeutics Inc. will jointly collaborate on a combination drug treatment for Duchenne muscular dystrophy (DMD), a rare and fatal genetic disease caused by a mutation in the dystrophin gene, a protein essential to muscle function.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register